Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $16.74 million versus the consensus estimate of $17.54 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.